Marinomed Biotech has announced that Fidia Farmaceutici will begin marketing Marinomed's Carragelose-based nasal sprays in Italy in Fall 2020, and Sanova Pharma has signed an agreement to launch the new Carravin nasal spray in Austria in 2021, subject to approval. The company's Carregelose products are already available in a number of European countries, as well as … [Read more...] about Marinomed announces upcoming launches of its nasal sprays in Italy and Austria
News
Vectura appoints three new Business Development Directors
Inhaled drug CDMO Vectura has announced the appointments of Trevor Archbold, Robert Gurley, and Chris Vernall as Business Development Directors, reporting to recently appointed Chief Commercial Officer Mark Bridgewater. Archbold and Vernall will cover Europe; Gurley will be responsible for the US West Coast. Archbold was most recently Strategic Account Manager, … [Read more...] about Vectura appoints three new Business Development Directors
Respira Technologies launches RespiRx nebulizer platform
Vaping startup Respira Technologies has announced the launch of its RespiRx delivery device platform, which the company is aiming at pharmaceutical drug delivery "across the fullest spectrum of pressure and thermo sensitive APIs." The company, which has backing from several venture capital companies, says that it is now a "a platform device and biotechnology company … [Read more...] about Respira Technologies launches RespiRx nebulizer platform
Phase 2a trial of Novus’s OP0201 nasal MDI for otitis media fails to meet primary endpoints
Novus Therapeutics said that a Phase 2a clinical trial of its OP0201 intranasal surfactant MDI for the treatment of acute otitis media in infants and children failed to meet its primary endpoints of "resolution of bulging tympanic membrane at visit 2 and resolution of middle ear effusion at visit 3." The study did show greater resolution of middle ear effusion for … [Read more...] about Phase 2a trial of Novus’s OP0201 nasal MDI for otitis media fails to meet primary endpoints
Altimmune announces initiation of Phase 1/2 trial of T-COVID intranasal therapy for COVID-19
Altimmune announced that the FDA has approved the company's IND for a Phase 1/2 clinical trial of its T-COVID intranasal therapy for the treatment of COVID-19, with data expected to be available in the fourth quarter of 2020. Earlier this year, Altimmune announced a partnership with the University of Alabama Birmingham for development of an intranasal vaccine for … [Read more...] about Altimmune announces initiation of Phase 1/2 trial of T-COVID intranasal therapy for COVID-19
Atossa Therapeutics announces development of intranasal therapy for mild COVID-19
Atossa Therapeutics announced that it has signed an agreement with Summit Biosciences for development and manufacturing of an intranasal formulation of Atossa's AT-301 as a candidate for the treatment of mild COVID-19, and it plans to submit an IND for clinical trials expected to begin in the third quarter of this year. The company said it is also investigating the … [Read more...] about Atossa Therapeutics announces development of intranasal therapy for mild COVID-19
Iconovo’s ICOcap DPI gets CE mark for clinical trial use
DPI developer Iconovo announced that the company's ICOcap capsule-based dry powder inhaler ICOcap is now CE marked for use in clinical trials. The ICOcap inhaler is available from the Stevanato Group, which signed a manufacturing, sales, and distribution agreement for the inhaler with Iconovo in 2018. Iconovo CEO Johan Wäborg commented, "Getting the CE … [Read more...] about Iconovo’s ICOcap DPI gets CE mark for clinical trial use
CARB-X and CF Foundation award Microbion grants worth up to $17 million for development of inhaled pravisbismane
Microbion Corporation said that it has received a grant worth up to $11.5 million from global non-profit CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and a grant worth up to $5.6 million from the Cystic Fibrosis Foundation (CFF) for pre-clinical and Phase 1 development of its pravibismane inhalation suspension for the treatment of … [Read more...] about CARB-X and CF Foundation award Microbion grants worth up to $17 million for development of inhaled pravisbismane
Microbion gets orphan designation for pravibismane inhalation suspension for lung infections in CF patients
Microbion Corporation said that its pravibismane inhalation suspension for the treatment of lung infections in patients with cystic fibrosis has been granted orphan drug designation by the FDA. Pravibismane inhalation suspension has already been granted Fast Track and Qualified Infectious Disease Product (QIDP) designations for that indication. According to the … [Read more...] about Microbion gets orphan designation for pravibismane inhalation suspension for lung infections in CF patients
Propeller Health sensor for Symbicort gets 510(k) clearance
Propeller Health announced that the FDA has granted 510(k) clearance for the company's inhaler monitoring sensor for AstraZeneca's Symbicort MDI. The Propeller sensor snaps on to the inhaler and connects via Bluetooth to a mobile app. The company also manufactures sensors for MDIs, DPIs, and SMIs made by GSK, Novartis, Orion, and Boehringer Ingelheim. Propeller … [Read more...] about Propeller Health sensor for Symbicort gets 510(k) clearance